TB Test Could Close the Diagnostic Gap in HIV hotspots
Researchers have developed a handheld TB test that accurately detects tuberculosis in HIV-positive individuals using a single drop of blood.
Researchers have developed a handheld TB test that accurately detects tuberculosis in HIV-positive individuals using a single drop of blood.
A diagnostic device using dielectrophoresis holds promise for improving tuberculosis detection and treatment of patients in high-endemic, under-resourced areas.
There has been a shift away from using tuberculin skin tests to modern TB blood tests—known as interferon gamma release assays (IGRAs).
Positive and negative controls are designed to help laboratories deliver reliable MTB-RIF testing results.
Read MoreThe funding will enable Lophius to expand clinical performance data and finalize design of the assay for use on automated platforms.
Read MoreSeries C funding will finance further development and CE marking of the company’s first molecular point-of-care platform based on pulse-controlled amplification technology.
Read MoreAccess to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals.
Read MoreStudy data show that the metabolic sensor mTOR contributes on the genetic level to the development of sarcoidosis.
Read MoreContinued validation of Lophius’ development capabilities bodes well as the company advances into tuberculosis diagnostics as its next focus area.
Read MoreThe BD Max MDR-TB panel has obtained the CE mark, supporting market launch in Europe.
Read MoreProtecting sample stability ensures the utility of the latest generation of TB tests.
Read MoreThe analytic visualization tool can be used to discover, grade, and track key bacterial drug-resistance mutations.
Read MoreThe landmark NIH study represents a major advance in tuberculosis research.
Read MoreCepheid has signed a memorandum of understanding representing its intention to work with USAID to support the White House’s national action plan for combating MDR-TB.
Read MoreA multiyear grant from the Bill & Melinda Gates Foundation will fund an innovative global data platform
 designed to streamline tuberculosis diagnosis and treatment.
Read MoreResults are available to clinicians in approximately 2 hours.
Read MoreThird-party R&D lab achieves 5-day tuberculosis detection, compared to weeks for standard tests.
Read MoreCepheid announced that its Xpert MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), “Rapid Molecular Detection of Tuberculosis and Rifampin Resistance.”
Read More